(Q40483401)

English

Evaluation of polyethylene glycol modification of first-generation and helper-dependent adenoviral vectors to reduce innate immune responses

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Evaluation of polyethylene glycol modification of first-generation and helper-dependent adenoviral vectors to reduce innate immune responses (English)

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

1 reference

based on heuristic

inferred from title

author name string

Hoyin Mok

1

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Donna J Palmer

2

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Philip Ng

3

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Michael A Barry

4

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

publication date

1 January 2005

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Molecular Therapy

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

11

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

1

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

66-79

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Activation of innate immunity in nonhuman primates following intraportal administration of adenoviral vectors.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.09.015

7 January 2021

Systemic interleukin-6 responses following administration of adenovirus gene transfer vectors to humans by different routes

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.09.015

7 January 2021

Long-term humoral and cellular immunity induced by a single immunization with replication-defective adenovirus recombinant vector

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.09.015

7 January 2021

Serum and ascites neutralizing antibodies in ovarian cancer patients treated with intraperitoneal adenoviral gene therapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.09.015

7 January 2021

Impact of preimmunization on adenoviral vector expression and toxicity in a subcutaneous mouse cancer model

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.09.015

7 January 2021

Preexisting immunity to adenovirus in rhesus monkeys fails to prevent vector-induced toxicity

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.09.015

7 January 2021

FK506 immunosuppression to control the immune reactions triggered by first-generation adenovirus-mediated gene transfer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.09.015

7 January 2021

An adenoviral vector deleted for all viral coding sequences results in enhanced safety and extended expression of a leptin transgene

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.09.015

7 January 2021

Administration of helper-dependent adenoviral vectors and sequential delivery of different vector serotype for long-term liver-directed gene transfer in baboons

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.09.015

7 January 2021

Helper-dependent adenovirus vectors elicit intact innate but attenuated adaptive host immune responses in vivo

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.09.015

7 January 2021

Acute toxicity after high-dose systemic injection of helper-dependent adenoviral vectors into nonhuman primates.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.09.015

7 January 2021

PEGylation of adenovirus with retention of infectivity and protection from neutralizing antibody in vitro and in vivo.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.09.015

7 January 2021

"Stealth" adenoviruses blunt cell-mediated and humoral immune responses against the virus and allow for significant gene expression upon readministration in the lung

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.09.015

7 January 2021

Blood clearance rates of adenovirus type 5 in mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.09.015

7 January 2021

Improved system for helper-dependent adenoviral vector production

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.09.015

7 January 2021

Adenovirus serotype 5 fiber shaft influences in vivo gene transfer in mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.09.015

7 January 2021

A novel strategy to modify adenovirus tropism and enhance transgene delivery to activated vascular endothelial cells in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.09.015

7 January 2021

The magnetofection method: using magnetic force to enhance gene delivery.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.09.015

7 January 2021

Avidin-based targeting and purification of a protein IX-modified, metabolically biotinylated adenoviral vector.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.09.015

7 January 2021

Adenovirus-Mediated Granulocyte-Macrophage Colony-Stimulating Factor Improves Lung Pathology of Pulmonary Alveolar Proteinosis in Granulocyte-Macrophage Colony-Stimulating Factor-Deficient Mice

2 references

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.09.015

7 January 2021

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.09.015

7 January 2021

based on heuristic

inferred from DOI database lookup

The release of inflammatory cytokines from human peripheral blood mononuclear cells in vitro following exposure to adenovirus variants and capsid

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.09.015

7 January 2021

CAR-binding ablation does not change biodistribution and toxicity of adenoviral vectors

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.09.015

7 January 2021

Liver toxicities typically induced by first-generation adenoviral vectors can be reduced by use of E1, E2b-deleted adenoviral vectors

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.09.015

7 January 2021

Simultaneous CAR- and alpha V integrin-binding ablation fails to reduce Ad5 liver tropism

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.09.015

7 January 2021

Adenoviral gene therapy leads to rapid induction of multiple chemokines and acute neutrophil-dependent hepatic injury in vivo

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.09.015

7 January 2021

Adenovirus vector-induced expression of the C-X-C chemokine IP-10 is mediated through capsid-dependent activation of NF-kappaB.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.09.015

7 January 2021

Molecular basis of the inflammatory response to adenovirus vectors

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.09.015

7 January 2021

Construction of adenoviral vectors

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.09.015

7 January 2021

Synthetic peptide vaccines: palmitoylation of peptide antigens by a thioester bond increases immunogenicity

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.09.015

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/J.YMTHE.2004.09.015

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40483401&oldid=1898075069"